Growth hormone releasing factor infusion does not sustain elevated GH-levels in normal subjects

in European Journal of Endocrinology
Authors:
Marco Losa
Search for other papers by Marco Losa in
Current site
Google Scholar
PubMed
Close
,
Lilian Bock
Search for other papers by Lilian Bock in
Current site
Google Scholar
PubMed
Close
,
Jochen Schopohl
Search for other papers by Jochen Schopohl in
Current site
Google Scholar
PubMed
Close
,
Günter K. Stalla
Search for other papers by Günter K. Stalla in
Current site
Google Scholar
PubMed
Close
,
O. Albrecht Müller
Search for other papers by O. Albrecht Müller in
Current site
Google Scholar
PubMed
Close
, and
Klaus von Werder
Search for other papers by Klaus von Werder in
Current site
Google Scholar
PubMed
Close
Restricted access

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

Abstract. To evaluate the dynamics of GH-secretion after infusion of growth hormone releasing factor, human pancreatic growth hormone releasing factor (hpGRF1-44) was infused over 2 and 5 h at a dosage of 100 μg hpGRF1-44/h into 11 healthy subjects. The infusion was started and terminated with a 50 μg hpGRF1-44 bolus injection. In 5 subjects 200 μg TRH was given 4 h after starting the infusion. In addition, 4 healthy subjects received 50 μg hpGRF1-44 bolus injection every 2 h. GRF, somatostatin, GH, Prl, and TSH were measured by radioimmunoassay.

The initial 50 μg GRF bolus increased GH-levels in all 11 subjects with a maximum at 30 min (24.1 ± 5.1 ng/ml ± se). However, though hpGRF1-44 was continuously infused and GFR-levels remained elevated, GH decreased to a minimum 270 min after start of infusion (2.6 ± 0.6 ng/ml). The GH-response to the second bolus at the end of the infusion was lower compared to the first response (14.6 ± 3.4 ng/ml after 2 h and 7.6 ± 2.5 ng/ml after 5 h). TRH did not lead to a GH-increase during hpGRF1-44 infusion though Prl and TSH rose normally. The intermittent bolus injection of 50 μg hpGRF1-44 led to continuously decreasing GH-responses to the same GRF-dosage (I. bolus: 16.5 ± 1.6 ng/ml; II. bolus: 4.2 ± 0.8 ng/ml; III. bolus: 3.4 ± 0.5 ng/ml). No change in somatostatin levels was observed.

These findings show that GRF infusion or bolus injection in short intervals does not sustain elevated GH-levels. Pituitary GH is either not readily available for continuous GRF-stimulation or GH-secretion may be antagonized by increasing portal somatostatin levels which are not reflected in the peripheral circulation.

 

  • Collapse
  • Expand

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 62 62 5
Full Text Views 0 0 0
PDF Downloads 1 1 0